Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Completed
- Conditions
- Hypertrophic Cardiomyopathy
- Registration Number
- NCT02234336
- Lead Sponsor
- Mayo Clinic
- Brief Summary
Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison of imaging modalities for this key measurement is lacking. This study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.
- Detailed Description
Patients receiving clinically indicated echocardiograms and cardiac magnetic resonance imaging at Mayo Clinic will be eligible.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
- Clinically and echocardiographically defined hypertrophic cardiomyopathy.
- Clinically indicated transthoracic echocardiography as part of the medical evaluation.
- No contradiction to administration of ultrasonic echocardiography contrast.
- Planned clinically indicated cardiac magnetic resonance imaging as part of medical evaluation.
- No contraindication to cardiac magnetic resonance imaging (such as cochlear implants, central nervous system aneurysm clips and other implanted medical devices).
- Age 18 years and older
Exclusion Criteria
- Insufficient image quality for determination of maximal wall thickness.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Left Ventricular Wall Thickness approximately 1 week after enrollment All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States
Mayo Clinic in Rochester🇺🇸Rochester, Minnesota, United States